Targeted next‐generation sequencing and non‐coding RNA expression analysis of clear cell papillary renal cell carcinoma suggests distinct pathological mechanisms from other renal tumour subtypes

Clear cell tubulopapillary renal cell carcinoma (CCPRCC) is a recently described rare renal malignancy that displays characteristic gross, microscopic and immunohistochemical differences from other renal tumour types. However, CCPRCC remains a very poorly understood entity. We therefore sought to elucidate some of the molecular mechanisms involved in this neoplasm by carrying out targeted next‐generation sequencing (NGS) to identify associated mutations, and in addition examined the expression of non‐coding (nc) RNAs. We identified multiple somatic mutations in CCPRCC cases, including a recurrent [3/14 cases (21%)] non‐synonymous T992I mutation in the MET proto‐oncogene, a gene associated with epithelial‐to‐mesenchymal transition (EMT). Using a microarray approach, we found that the expression of mature (n = 1105) and pre‐miRNAs (n = 1105), as well as snoRNA and scaRNAs (n = 2214), in CCPRCC cases differed from that of clear cell renal cell carcinoma (CCRCC) or papillary renal cell carcinoma (PRCC) tumours. Surprisingly, and unlike other renal tumour subtypes, we found that all five members of the miR‐200 family were over‐expressed in CCPRCC cases. As these miRNAs are intimately involved with EMT, we stained CCPRCC cases for E‐cadherin, vimentin and β‐catenin and found that the tumour cells of all cases were positive for all three markers, a combination rarely reported in other renal tumours that could have diagnostic implications. Taken together with the mutational analysis, these data suggest that EMT in CCPRCC tumour cells is incomplete or blocked, consistent with the indolent clinical course typical of this malignancy. In summary, as well as describing a novel pathological mechanism in renal carcinomas, this study adds to the mounting evidence that CCPRCC should be formally considered a distinct entity. Microarray data have been deposited in the GEO database [GEO accession number (GSE51554)]. Copyright © 2013 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

[1]  M. V. van Dijk,et al.  The entire miR‐200 seed family is strongly deregulated in clear cell renal cell cancer compared to the proximal tubular epithelial cells of the kidney , 2013, Genes, chromosomes & cancer.

[2]  Xiaokun Zhao,et al.  microRNA-155 silencing inhibits proliferation and migration and induces apoptosis by upregulating BACH1 in renal cancer cells , 2012, Molecular medicine reports.

[3]  R. Dahiya,et al.  MicroRNA-34a suppresses malignant transformation by targeting c-Myc transcriptional complexes in human renal cell carcinoma. , 2012, Carcinogenesis.

[4]  Huiqing Liu,et al.  Identifying mRNA targets of microRNA dysregulated in cancer: with application to clear cell Renal Cell Carcinoma , 2010, BMC Systems Biology.

[5]  Yuri E Nikiforov,et al.  Pulmonary Langerhans cell histiocytosis: profiling of multifocal tumors using next-generation sequencing identifies concordant occurrence of BRAF V600E mutations. , 2013, Chest.

[6]  R. Shah,et al.  Renal Cell Carcinomas With Papillary Architecture and Clear Cell Components: The Utility of Immunohistochemical and Cytogenetical Analyses in Differential Diagnosis , 2008, The American journal of surgical pathology.

[7]  A. Gerger,et al.  MicroRNAs in renal cell carcinoma: implications for pathogenesis, diagnosis, prognosis and therapy. , 2012, Anticancer research.

[8]  M. Seto,et al.  Genome‐wide microRNA expression profiling in renal cell carcinoma: significant down‐regulation of miR‐141 and miR‐200c , 2008, The Journal of pathology.

[9]  Y Dai,et al.  Microarray analysis of microRNA expression in renal clear cell carcinoma. , 2009, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[10]  George M Yousef,et al.  Differential expression profiling of microRNAs and their potential involvement in renal cell carcinoma pathogenesis. , 2010, Clinical biochemistry.

[11]  C. Pan,et al.  Clear cell papillary renal cell carcinoma and clear cell renal cell carcinoma arising in acquired cystic disease of the kidney: an immunohistochemical and genetic study. , 2011, Annals of diagnostic pathology.

[12]  Andrea J. O'Hara,et al.  Gene alteration and precursor and mature microRNA transcription changes contribute to the miRNA signature of primary effusion lymphoma. , 2008, Blood.

[13]  D. Grignon,et al.  Clear cell papillary renal cell carcinoma: differential diagnosis and extended immunohistochemical profile , 2013, Modern Pathology.

[14]  P. Schirmacher,et al.  VHL alterations in human clear cell renal cell carcinoma: association with advanced tumor stage and a novel hot spot mutation. , 2000, Cancer research.

[15]  J. Ragoussis,et al.  The role of hypoxia regulated microRNAs in cancer. , 2010, Current topics in microbiology and immunology.

[16]  D. Grignon,et al.  Clear Cell Papillary Renal Cell Carcinoma–like Tumors in Patients With Von Hippel-Lindau Disease Are Unrelated to Sporadic Clear Cell Papillary Renal Cell Carcinoma , 2013, The American journal of surgical pathology.

[17]  B. Delahunt,et al.  Clear Cell Tubulopapillary Renal Cell Carcinoma: A Study of 36 Distinctive Low-grade Epithelial Tumors of the Kidney , 2010, The American journal of surgical pathology.

[18]  M. Korpal,et al.  The miR-200 Family Inhibits Epithelial-Mesenchymal Transition and Cancer Cell Migration by Direct Targeting of E-cadherin Transcriptional Repressors ZEB1 and ZEB2* , 2008, Journal of Biological Chemistry.

[19]  Hanlin Gao,et al.  MicroRNA profiling of clear cell renal cell carcinoma by whole‐genome small RNA deep sequencing of paired frozen and formalin‐fixed, paraffin‐embedded tissue specimens , 2010, The Journal of pathology.

[20]  A. Belldegrun,et al.  Pathological, immunohistochemical and cytogenetic features of papillary renal cell carcinoma with clear cell features. , 2011, The Journal of urology.

[21]  Antonio Lopez-Beltran,et al.  2004 WHO classification of the renal tumors of the adults. , 2006, European urology.

[22]  V. Reuter,et al.  Differential Diagnosis of Renal Tumors With Papillary Architecture , 2011, Advances in anatomic pathology.

[23]  Francisco E. Baralle,et al.  Genomic variants in exons and introns: identifying the splicing spoilers , 2004, Nature Reviews Genetics.

[24]  L. Truong,et al.  Immunohistochemical diagnosis of renal neoplasms. , 2011, Archives of pathology & laboratory medicine.

[25]  P. Brousset,et al.  Specific small nucleolar RNA expression profiles in acute leukemia , 2012, Leukemia.

[26]  Marek Svoboda,et al.  Expression of miRNA-106b in conventional renal cell carcinoma is a potential marker for prediction of early metastasis after nephrectomy , 2010, Journal of experimental & clinical cancer research : CR.

[27]  R. Figlin,et al.  Identification of a 4-microRNA Signature for Clear Cell Renal Cell Carcinoma Metastasis and Prognosis , 2012, PloS one.

[28]  K. Wagner,et al.  Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs11554137 is an adverse prognostic factor. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  Mingxia Xiong,et al.  The miR-200 family regulates TGF-β1-induced renal tubular epithelial to mesenchymal transition through Smad pathway by targeting ZEB1 and ZEB2 expression. , 2012, American journal of physiology. Renal physiology.

[30]  M. Sibony,et al.  Clear‐cell papillary renal cell carcinoma: 24 cases of a distinct low‐grade renal tumour and a comparative genomic hybridization array study of seven cases , 2011, Histopathology.

[31]  C. Kimchi-Sarfaty,et al.  Understanding the contribution of synonymous mutations to human disease , 2011, Nature Reviews Genetics.

[32]  W. Dinjens,et al.  Molecular diagnostics of a single multifocal non-small cell lung cancer case using targeted next generation sequencing , 2013, Virchows Archiv.

[33]  Jun Li,et al.  Biomarkers , Genomics , Proteomics , and Gene Regulation miR-182 as a Prognostic Marker for Glioma Progression and Patient Survival , 2010 .

[34]  P. Argani,et al.  Renal cell carcinoma with clear cell and papillary features. , 2012, Archives of pathology & laboratory medicine.

[35]  D. Polsky,et al.  Aberrant miR-182 expression promotes melanoma metastasis by repressing FOXO3 and microphthalmia-associated transcription factor , 2009, Proceedings of the National Academy of Sciences.

[36]  H. Aburatani,et al.  Papillary Renal Cell Carcinoma: Quantitation of Chromosomes 7 and 17 by FISH, Analysis of Chromosome 3p for LOH, and DNA Ploidy , 1996, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

[37]  R. Salgia,et al.  The role of the c-Met pathway in lung cancer and the potential for targeted therapy , 2011, Therapeutic advances in medical oncology.

[38]  Holger Moch,et al.  VHL mutations and their correlation with tumour cell proliferation, microvessel density, and patient prognosis in clear cell renal cell carcinoma , 2002, The Journal of pathology.

[39]  F. Marincola,et al.  Association between HRAS rs12628 and rs112587690 polymorphisms with the risk of melanoma in the North American population , 2012, Medical Oncology.

[40]  Jill P. Mesirov,et al.  MEDULLOBLASTOMA EXOME SEQUENCING UNCOVERS SUBTYPE-SPECIFIC SOMATIC MUTATIONS , 2012, Nature.

[41]  Bin Tean Teh,et al.  MicroRNA profiling of human kidney cancer subtypes. , 2009, International journal of oncology.

[42]  M. Korpal,et al.  The emerging role of miR-200 family of MicroRNAs in epithelial-mesenchymal transition and cancer metastasis , 2008, RNA biology.

[43]  J. Christensen,et al.  The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. , 2009, Cancer research.

[44]  B. Druker,et al.  MET receptor sequence variants R970C and T992I lack transforming capacity. , 2010, Cancer research.

[45]  N. Dubrawsky Cancer statistics , 1989, CA: a cancer journal for clinicians.

[46]  R. Albert,et al.  miR-200b restoration and DNA methyltransferase inhibitor block lung metastasis of mesenchymal-phenotype hepatocellular carcinoma , 2012, Oncogenesis.

[47]  K. Hoang-Xuan,et al.  Prognostic impact of the isocitrate dehydrogenase 1 single‐nucleotide polymorphism rs11554137 in malignant gliomas , 2013, Cancer.

[48]  Jörg Grigull,et al.  miRNA profiling for clear cell renal cell carcinoma: biomarker discovery and identification of potential controls and consequences of miRNA dysregulation. , 2011, The Journal of urology.

[49]  J. López Renal tumors with clear cells. A review. , 2013, Pathology, research and practice.

[50]  I. Thompson,et al.  Elevated snoRNA biogenesis is essential in breast cancer , 2014, Oncogene.

[51]  M. Seto,et al.  Overexpression of miR‐210, a downstream target of HIF1α, causes centrosome amplification in renal carcinoma cells , 2011, The Journal of pathology.

[52]  D. L. Souza,et al.  [Incidence, prevalence and mortality of kidney cancer in Spain: estimates and projections for the 1998-2022 period]. , 2012, Actas urologicas espanolas.

[53]  D. McCance Pathological Society of Great Britain and Ireland , 1984 .

[54]  M. Michael,et al.  The VHL-dependent regulation of microRNAs in renal cancer , 2010, BMC medicine.

[55]  Ling Wang,et al.  Pre-Micro RNA Signatures Delineate Stages of Endothelial Cell Transformation in Kaposi Sarcoma , 2009, PLoS pathogens.

[56]  F. Farzaneh,et al.  Are snoRNAs and snoRNA host genes new players in cancer? , 2012, Nature Reviews Cancer.

[57]  M. Rosenblum,et al.  Clear-cell papillary renal cell carcinoma: molecular and immunohistochemical analysis with emphasis on the von Hippel–Lindau gene and hypoxia-inducible factor pathway-related proteins , 2011, Modern Pathology.

[58]  Y. Nagashima,et al.  Pathological and molecular biological aspects of the renal epithelial neoplasms, up‐to‐date , 2004, Pathology international.

[59]  George A Calin,et al.  Micro-RNA profiling in kidney and bladder cancers. , 2007, Urologic oncology.

[60]  K. Mai,et al.  Renal cell carcinoma with mixed features of papillary and clear cell cytomorphology: a fluorescent in situ hybridization study , 2009, Virchows Archiv.

[61]  W. Birchmeier,et al.  Met, metastasis, motility and more , 2003, Nature Reviews Molecular Cell Biology.

[62]  S. Spivack,et al.  Overexpression of the microRNA hsa-miR-200c leads to reduced expression of transcription factor 8 and increased expression of E-cadherin. , 2007, Cancer research.

[63]  George M Yousef,et al.  The miR-17-92 cluster is over expressed in and has an oncogenic effect on renal cell carcinoma. , 2010, The Journal of urology.

[64]  Hongbing Shen,et al.  A germline variant N375S in MET and gastric cancer susceptibility in a Chinese population , 2012, Journal of biomedical research.

[65]  P. Grossmann,et al.  Clonal trisomies 7,10 and 12, normal 3p and absence of VHL gene mutation in a clear cell tubulopapillary carcinoma of the kidney , 2011, Virchows Archiv.

[66]  W. Linehan,et al.  Novel mutations of the MET proto-oncogene in papillary renal carcinomas , 1999, Oncogene.

[67]  G. Bhanot,et al.  Identification of a microRNA panel for clear-cell kidney cancer. , 2010, Urology.

[68]  M. Naujokas,et al.  Crk adapter proteins promote an epithelial-mesenchymal-like transition and are required for HGF-mediated cell spreading and breakdown of epithelial adherens junctions. , 2002, Molecular biology of the cell.

[69]  T. Matsuyama,et al.  Increase in hepatocyte growth factor receptor tyrosine kinase activity in renal carcinoma cells is associated with increased motility partly through phosphoinositide 3-kinase activation , 2001, Oncogene.

[70]  Sun-Mi Park,et al.  The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. , 2008, Genes & development.

[71]  S. Fröhling,et al.  High-throughput sequence analysis of the tyrosine kinome in acute myeloid leukemia. , 2007, Blood.

[72]  L. Strong,et al.  Activating mutation in MET oncogene in familial colorectal cancer , 2011, BMC Cancer.

[73]  J. Larkin,et al.  Epigenetic regulation in RCC: opportunities for therapeutic intervention? , 2012, Nature Reviews Urology.

[74]  P. Tassone,et al.  The expression pattern of small nucleolar and small Cajal body-specific RNAs characterizes distinct molecular subtypes of multiple myeloma , 2012, Blood Cancer Journal.

[75]  R. Lothe,et al.  MiR-9, -31, and -182 deregulation promote proliferation and tumor cell survival in colon cancer. , 2012, Neoplasia.

[76]  L. Schmidt,et al.  A novel germ line juxtamembrane Met mutation in human gastric cancer , 2000, Oncogene.

[77]  R. Shah,et al.  Clear Cell Papillary Renal Cell Carcinoma: A Distinct Histopathologic and Molecular Genetic Entity , 2008, The American journal of surgical pathology.

[78]  A. Jemal,et al.  Cancer statistics, 2013 , 2013, CA: a cancer journal for clinicians.

[79]  L. Truong,et al.  Role of immunohistochemistry in diagnosing renal neoplasms: when is it really useful? , 2012, Archives of pathology & laboratory medicine.

[80]  Jeong Hwan Park,et al.  Clear Cell Papillary Renal Cell Carcinoma: A Report of 15 Cases Including Three Cases of Concurrent Other-Type Renal Cell Carcinomas , 2012, Korean journal of pathology.

[81]  M. Esteller,et al.  Dynamic epigenetic regulation of the microRNA-200 family mediates epithelial and mesenchymal transitions in human tumorigenesis , 2011, Oncogene.

[82]  T. Enver,et al.  MicroRNA expression in lymphocyte development and malignancy , 2008, Leukemia.

[83]  P. Hirvikoski,et al.  Evaluation of myosin VI, E-cadherin and beta-catenin immunostaining in renal cell carcinoma , 2010, Journal of experimental & clinical cancer research : CR.